Michael R. Jirousek

8.9k citations

60 papers · 4.7k indexed · 2 hit papers · h-index 29

Co-authors: Jacques Ermolieff Theodore Johnson Peter G. Goekjian James M. Trevillyan George L. King Jill C. Milne Peter J. Elliott J. Joshua Smith
Topics: Protein Tyrosine Phosphatases (15 papers)Protein Kinase Regulation and GTPase Signaling (11 papers)Galectins and Cancer Biology (11 papers)
Cited by: Geriatrics and Gerontology Toxicology Physiology
Journals: Proceedings of the National Academy of Sciences Journal of the American Chemical Society Journal of Biological Chemistry
Partner nations: United States United Kingdom China

In The Last Decade

Michael R. Jirousek

59 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Protein tyrosine phosphatase 1B inhibitors for diabetes

2002 564 citations Theodore Johnson, Jacques Ermolieff et al. Nature Reviews Drug Discovery profile →
Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor

1997 515 citations Lloyd Paul Aiello, Allen C. Clermont et al. Diabetes profile →

Peers

Countries citing papers authored by Michael R. Jirousek

Since Specialization

Citations

This map shows the geographic impact of Michael R. Jirousek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Jirousek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Jirousek more than expected).

Fields of papers citing papers by Michael R. Jirousek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Jirousek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Jirousek. The network helps show where Michael R. Jirousek may publish in the future.

Co-authorship network of co-authors of Michael R. Jirousek

This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. Jirousek. A scholar is included among the top collaborators of Michael R. Jirousek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. Jirousek. Michael R. Jirousek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CAT‐2003: A novel sterol regulatory element‐binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E3‐Leiden mice 2017 ·Hepatology Communications* ·Michael Zimmer,Pradeep Bista,(unknown),Diana Lee,Feng Liu,Dominic Picarella,Rick B. Vega,Chi B. Vu,(unknown),Min Ding,Guosheng Liang,Jay D. Horton,Robert Kleemann,Teake Kooistra,Martine C. Morrison,Peter Y. Wielinga,Jill C. Milne,Michael R. Jirousek,Andrew J. Nichols	17
2	Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle 2016 ·JCI Insight ·David W. Hammers,Margaret M. Sleeper,Sean C. Forbes,(unknown),Michael R. Jirousek,Michael Zimmer,Glenn A. Walter,H. Lee Sweeney	40
3	PHASE 1 SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF CAT-2003, A NOVEL ACTIVATOR OF LIPOPROTEIN LIPASE, DEMONSTRATES REDUCTIONS IN POSTPRANDIAL TRIGLYCERIDES 2014 ·Journal of the American College of Cardiology ·Joanne M. Donovan,Richard L. Dunbar,(unknown),Douglas Logan,Michael J. Curtis,Maria Mancini,Michael R. Jirousek	6
4	Discovery of Imidazo[1,2- b ]thiazole Derivatives as Novel SIRT1 Activators 2009 ·Journal of Medicinal Chemistry ·Chi B. Vu,Jean E. Bemis,Jeremy S. Disch,Pui Yee Ng,Joseph J. Nunes,Jill C. Milne,David P. Carney,(unknown),J. Joshua Smith,Siva Lavu,Philip Lambert,David Gagné,Michael R. Jirousek,Simon Schenk,Jerrold M. Olefsky,Robert B. Perni	101
5	Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo 2009 ·BMC Systems Biology ·J. Joshua Smith,(unknown),David Gagné,Brian P. Frushour,William Ladd,Heidi L. Galonek,(unknown),Jeffrey Song,(unknown),(unknown),David P. Carney,Robin J. Johnson,Siva Lavu,André Iffland,Peter J. Elliott,Philip Lambert,Keith Elliston,Michael R. Jirousek,Jill C. Milne,Olivier Boss	168
6	Discovery of benzothiazole derivatives as efficacious and enterocyte-specific MTP inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Chi B. Vu,Jill C. Milne,David P. Carney,Jeffrey Song,(unknown),Philip Lambert,David Gagné,Michael L. Hirsch,(unknown),Meghan F. Davis,(unknown),(unknown),Karl Normington,Michael R. Jirousek,Robert B. Perni	23
7	Crystal Structures of Human SIRT3 Displaying Substrate-induced Conformational Changes 2009 ·Journal of Biological Chemistry ·Lei Jin,Wentao Wei,(unknown),(unknown),CAI JIAN-HUA,Mao Chen,Han Dai,(unknown),Jean E. Bemis,Michael R. Jirousek,Jill C. Milne,Christoph Westphal,Robert B. Perni	176
8	Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Hongyu Zhao,Gang Liu,Zhili Xin,Michael D. Serby,Zhonghua Pei,Bruce G. Szczepankiewicz,Philip J. Hajduk,Cele Abad‐Zapatero,Charles W. Hutchins,Thomas Lübben,Stephen J. Ballaron,Deanna L. Haasch,Wiweka Kaszubska,Cristina M. Rondinone,James M. Trevillyan,Michael R. Jirousek	74
9	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ 2003 ·Bioorganic & Medicinal Chemistry Letters ·Margaret M. Faul,James R. Gillig,Michael R. Jirousek,Lawrence M. Ballas,Theo Schotten,(unknown),Michael Möhr	83
10	Identification of a monoacid-Based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B 2003 ·Bioorganic & Medicinal Chemistry Letters ·Zhili Xin,Gang Liu,Cele Abad‐Zapatero,Zhonghua Pei,Bruce G. Szczepankiewicz,Xiaofeng Li,Tianyuan Zhang,Charles W. Hutchins,Philip J. Hajduk,Stephen J. Ballaron,Michael A. Stashko,Thomas Lübben,James M. Trevillyan,Michael R. Jirousek	52
11	PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat 2003 ·Molecular and Cellular Endocrinology ·Jeffrey F. Waring,Rita Ciurlionis,Jill E. Clampit,Sherry J. Morgan,Rebecca J. Gum,Robert A. Jolly,Paul Kroeger,Leigh Frost,James M. Trevillyan,Bradley A. Zinker,Michael R. Jirousek,Roger G. Ulrich,Cristina M. Rondinone	33
12	Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Zhonghua Pei,Xiaofeng Li,Gang Liu,Cele Abad‐Zapatero,(unknown),Tianyuan Zhang,Stephen J. Ballaron,Charles W. Hutchins,James M. Trevillyan,Michael R. Jirousek	23
13	Protein tyrosine phosphatase 1B inhibitors for diabetesbreakdown → 2002 ·Nature Reviews Drug Discovery ·Theodore Johnson,Jacques Ermolieff,Michael R. Jirousek	564
14	Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line 2002 ·Molecular and Cellular Endocrinology ·Wiweka Kaszubska,Hugh D. Falls,Verlyn G. Schaefer,Deanna L. Haasch,Leigh Frost,Paul Hessler,Paul E. Kroeger,David W. White,Michael R. Jirousek,James M. Trevillyan	150
15	Protein kinase C inhibitors as novel anticancer drugs 2001 ·Expert Opinion on Investigational Drugs ·Michael R. Jirousek,Peter G. Goekjian	153
16	In Vitro Enzymatic Assays of Protein Tyrosine Phosphatase 1B 2001 ·Current Protocols in Pharmacology ·Thomas Lübben,Jill E. Clampit,Michael A. Stashko,James M. Trevillyan,Michael R. Jirousek	10
17	Protein Kinase C in the Treatment of Disease: Signal Transduction Pathways, Inhibitors, and Agents in Development 1999 ·Current Medicinal Chemistry ·Peter G. Goekjian,Michael R. Jirousek	121
18	Effects of protein kinase C inhibitors on thromboxane production by thrombin-stimulated platelets 1999 ·European Journal of Pharmacology ·Gennady P. Samokhin,Michael R. Jirousek,D. Kirk Ways,Ruth Ann Henriksen	9
19	Synthesis of bisindolylmaleimides using a palladium catalyzed cross-coupling reaction 1998 ·Bioorganic & Medicinal Chemistry Letters ·David A. Neel,Michael R. Jirousek,John H. McDonald	18
20	Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitorbreakdown → 1997 ·Diabetes ·Lloyd Paul Aiello,(unknown),Allen C. Clermont,Elia J. Duh,Hidehiro Ishii,Chikako Takagi,Fumi Mori,Thomas A. Ciulla,Kirk Ways,Michael R. Jirousek,Lois E. H. Smith,George L. King	515

About Michael R. Jirousek

Michael R. Jirousek is a scholar working on Toxicology, Geriatrics and Gerontology and Immunology, having authored 60 papers that have together received 4.7k indexed citations. Recurring topics across this work include Protein Tyrosine Phosphatases (15 papers), Protein Kinase Regulation and GTPase Signaling (11 papers) and Galectins and Cancer Biology (11 papers). The work is most often cited by research in Geriatrics and Gerontology (739 citations), Toxicology (340 citations) and Physiology (210 citations). Michael R. Jirousek has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Jacques Ermolieff, Theodore Johnson, Peter G. Goekjian, James M. Trevillyan, George L. King, Jill C. Milne, Peter J. Elliott, J. Joshua Smith, Cristina M. Rondinone and Zhonghua Pei. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact